Marked Expansion of Exocrine and Endocrine Pancreas With Incretin Therapy in Humans With Increased Exocrine Pancreas Dysplasia and the Potential for Glucagon-Producing Neuroendocrine Tumors
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Controversy exists regarding the potential regenerative influences of incretin therapy on pancreatic β-cells versus possible adverse pancreatic proliferative effects. Examination of pancreata from age-matched organ donors with type 2 diabetes mellitus (DM) treated by incretin therapy (n = 8) or other therapy (n = 12) and nondiabetic control subjects (n = 14) reveals an ∼40% increased pancreatic mass in DM treated with incretin therapy, with both increased exocrine cell proliferation (P < 0.0001) and dysplasia (increased pancreatic intraepithelial neoplasia, P < 0.01). Pancreata in DM treated with incretin therapy were notable for α-cell hyperplasia and glucagon-expressing microadenomas (3 of 8) and a neuroendocrine tumor. β-Cell mass was reduced by ∼60% in those with DM, yet a sixfold increase was observed in incretin-treated subjects, although DM persisted. Endocrine cells costaining for insulin and glucagon were increased in DM compared with non-DM control subjects (P < 0.05) and markedly further increased by incretin therapy (P < 0.05). In conclusion, incretin therapy in humans resulted in a marked expansion of the exocrine and endocrine pancreatic compartments, the former being accompanied by increased proliferation and dysplasia and the latter by α-cell hyperplasia with the potential for evolution into neuroendocrine tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Pancreatic, intestinal, and breast neoplasms were more frequently developed in rodents administered with incretin-based medications”
From Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? (2021) · cites this paper as [56]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“A decreased risk of colorectal adenomas and colorectal carcinoma is a consistent finding with a potential for a survival benefit for colorectal carcinoma.1784–1790”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1788]
Experimental — accuracy not yet measuredIn the citing paper
“these results were not confirmed in human studies [56–58].”
From Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? (2021) · cites this paper as [56]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
Self-citationXu, G., Stoffers, D. A., Habener, J. F., & Bonner-Weir, S. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2270 · Cited by 1,209
Conversion of adult pancreatic α-cells to β-cells after extreme β-cell loss
Thorel, F., Népote, V., Avril, I., Kohno, K., Desgraz, R., Chera, S., & Herrera, P. L. (2010) · Nature · doi:10.1038/nature08894 · Cited by 1,136
Hruban, R. H., Takaori, K., Klimstra, D. S., Adsay, N. V., Albores-Saavedra, J., Biankin, A. V., Biankin, S. A., Compton, C., Fukushima, N., Furukawa, T., et al. (2004) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000126675.59108.80 · Cited by 1,091
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944
Self-citationZulewski, H., Abraham, E. J., Gerlach, M. J., Daniel, P. B., Moritz, W., Müller, B., Vallejo, M., Thomas, M. K., & Habener, J. F. (2001) · Diabetes · doi:10.2337/diabetes.50.3.521 · Cited by 785
Pancreatic β‐cell mass in European subjects with type 2 diabetes
Rahier, J., Guiot, Y., Goebbels, R. M., Sempoux, C., & Henquin, J. C. (2008) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00969.x · Cited by 756
Selective β-Cell Loss and α-Cell Expansion in Patients with Type 2 Diabetes Mellitus in Korea
Yoon, K. H., Ko, S. H., Cho, J. H., Lee, J. M., Ahn, Y. B., Song, K. H., Yoo, S. J., Kang, M. I., Cha, B. Y., Lee, K. W., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020735 · Cited by 649
Islet Pathology and the Pathogenesis of Type 1 and Type 2 Diabetes mellitus Revisited
Klöppel, G., Löhr, M., Habich, K., Oberholzer, M., & Heitz, P. U. (1985) · Pathology and Immunopathology Research · doi:10.1159/000156969 · Cited by 577
Gelling, R. W., Du, X. Q., Dichmann, D. S., Rømer, J., Huang, H., Cui, L., Obici, S., Tang, B., Holst, J. J., Fledelius, C., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0237106100 · Cited by 563
Cited by
Items 301–400 of 460
Kang, M., Fěng, F., Ge, Q., Zhu, F., Chen, L., Lv, P., Ma, S., Yao, Q., & Chen, K. (2020) · Journal of Applied Microbiology · doi:10.1111/jam.14729 · Cited by 6
β‐Cell mass and function in human type 2 diabetes
Marchetti, P., & Ferrannini, E. (2015) · Wiley eBooks · doi:10.1002/9781118387658.ch24 · Cited by 12
Pancreatic safety of GLP-1-based therapeutic agents: further insights from rodent studies?
Holst, J. J. (2013) · Diabetologia · doi:10.1007/s00125-013-2984-z · Cited by 6
Ruggeri, R. M., Grossrubatscher, E. M., Ciocca, E., Hasballa, I., Jaafar, S., Oldani, M., Rubino, M., Russo, F., Isidori, A. M., Colao, A. A. L., et al. (2025) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-025-09958-5 · Cited by 5
Barrea, L., Caprio, M., Perrini, S., Camajani, E., Crafa, A., Gangitano, E., Gorini, S., Sciacca, L., Verde, L., Albertelli, M., et al. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02589-2 · Cited by 5
Novo Nordisk replies to BMJ investigation on incretins and pancreatic damage
Moses, A. C. (2013) · BMJ · doi:10.1136/bmj.f4386 · Cited by 5
Inpatient glucocorticoid use: beneficence vs non-maleficence
Dhatariya, K. (2014) · British Journal of Hospital Medicine · doi:10.12968/hmed.2014.75.5.252 · Cited by 8
Breuer, T. G. K., Borker, L., Quast, D. R., Tannapfel, A., Schmidt, W. E., Uhl, W. H., & Meier, J. J. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0320 · Cited by 5
GLP-1(28-36)amide, the Glucagon-like peptide-1 metabolite: friend, foe, or pharmacological folly?
Whitehead, J. P., Taing, M., & Rose, F. J. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s35723 · Cited by 11
Prise en charge du diabète de type 2 : anciens ou nouveaux médicaments, comment choisir ?
Halimi, S. (2013) · La Presse Médicale · doi:10.1016/j.lpm.2013.04.002 · Cited by 6
Incretin-based therapies and pancreatitis risk: myth or reality
Pappachan, J. M. (2014) · Endocrine · doi:10.1007/s12020-014-0490-9 · Cited by 6
Lauri, G., Arcidiacono, P. G., Facciorusso, A., Capurso, G., & Tacelli, M. (2026) · Pancreatology · doi:10.1016/j.pan.2026.04.005 · Cited by 4
Chowdhury, T. A., & Bennett-Richards, P. (2013) · QJM · doi:10.1093/qjmed/hct150 · Cited by 4
Mahvash Disease: An Autosomal Recessive Hereditary Pancreatic Neuroendocrine Tumor Syndrome
Rhyu, J., & Yu, R. (2016) · International Journal of Endocrine Oncology · doi:10.2217/ije-2016-0005 · Cited by 5
Individualized, patient-centered use of lixisenatide for the treatment of type 2 diabetes mellitus
Hanefeld, M., Raccah, D., & Monnier, L. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1251579 · Cited by 5
Neuroendocrine tumors and diabetes mellitus: which treatment and which effect
Mazzilli, R., Zamponi, V., Mancini, C., Giorgini, B., Golisano, B., Mikovic, N., Pecora, G., Russo, F., Martiradonna, M., Paravani, P., et al. (2025) · Endocrine · doi:10.1007/s12020-024-04149-9 · Cited by 4
Acosta, A., Fanco, A., Rohan, H. P., & Elfessi, Z. Z. (2025) · JEM Reports · doi:10.1016/j.jemrpt.2025.100139 · Cited by 6
Studying Pancreatic Risks Caused by Incretin-Based Therapies
Nauck, M. A., & Meier, J. J. (2014) · Journal of Diabetes Science and Technology · doi:10.1177/1932296814532874 · Cited by 4
Srivastav, V. K., & Tiwari, M. (2021) · Indian Journal of Pharmaceutical Sciences · doi:10.36468/pharmaceutical-sciences.857 · Cited by 4
Gut hormones and Type 2 diabetes mellitus
Falinska, A. M., Tan, T., & Bloom, S. R. (2014) · Diabetes Management · doi:10.2217/dmt.14.47 · Cited by 4
Proglucagon-Derived Peptides Do Not Significantly Affect Acute Exocrine Pancreas in Rats
Akalestou, E., Christakis, I. A., Solomou, A., MINNION, J. S., Rutter, G. A., & Bloom, S. R. (2016) · Pancreas · doi:10.1097/mpa.0000000000000585 · Cited by 5
Are the Newer Antidiabetic Agents Worth the Cost?
Pemminati, S. (2016) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2016/17683.7384 · Cited by 4
Li, G., Long, X., Pan, Y., Xiao, M., & Zhao, X. (2018) · Biomedical Research - India · doi:10.4066/biomedicalresearch.29-17-3436 · Cited by 4
Can we exonerate GLP-1 receptor agonists from blame for adverse pancreatic events?
Murphy, C. F., & le Roux, C. W. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.03.06 · Cited by 4
Wei, R., & Hong, T. (2019) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.01.003 · Cited by 4
Facciorusso, A., Giannini, E. G., Tacelli, M., Zanetto, A., Spada, C., Boskoski, I., Furnari, M., Pennisi, G., Capurso, G., Vitello, A., et al. (2026) · Digestive and Liver Disease · doi:10.1016/j.dld.2026.02.018 · Cited by 3
Morehouse, Z. P., & Ledford, J. D. (2024) · Journal of Pharmacy Practice · doi:10.1177/08971900241273188 · Cited by 4
Non-functional alpha-cell hyperplasia with glucagon-producing NET: a case report
Cidade-Rodrigues, C., Santos, A. P., Calheiros, R., Santos, S., Matos, C., Moreira, A. P., Inácio, I. M. R., Souteiro, P., Oliveira, J., Jácome, M., et al. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1405835 · Cited by 4
Sympathovagal Imbalance in Type 2 Diabetes — Role of Brainstem Thyrotropin-Releasing Hormone
Yang, H. (2013) · InTech eBooks · doi:10.5772/56541 · Cited by 4
A Case Report of Acute Pancreatitis in Food-Induced Anaphylaxis
Wiese, J., Dakkak, B., Ugonabo, O. S., El-Dallal, M., & Frandah, W. (2024) · Cureus · doi:10.7759/cureus.71017 · Cited by 3
Effect of glucagon-like peptide-1 receptor agonists on prostate cancer: A review
Xu, Y., & Liu, J. (2024) · Medicine · doi:10.1097/md.0000000000039956 · Cited by 5
Blum, K., Dennen, C. A., Lewandrowski, K.-U., Sharafshah, A., Pinhasov, A., Bowirrat, A., Elman, I., Cadet, J. L., Braverman, E. R., Thanos, P. K., et al. (2025) · Medical Hypotheses · doi:10.1016/j.mehy.2025.111612 · Cited by 4
Torun, A. N., & Ertuğrul, D. T. (2015) · InTech eBooks · doi:10.5772/59241 · Cited by 4
Деякі аспекти медикаментозної терапії цукрового діабету 2-го типу у людей з надмірною масою тіла
Jargin, S. V. (2019) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.15.5.2019.180046 · Cited by 5
Тучина, Т. П., Скотникова, К. П., Anatolievna, V. A., Sergeyevich, U. I., Rogoza, O. V., Grozov, R. V., Yurievna, B. A., & Mikhailovich, G. M. (2021) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.238 · Cited by 3
Comparison of DPP-4 Inhibitors
Kim, N. H., & Kim, S. G. (2013) · Journal of Korean Diabetes · doi:10.4093/jkd.2013.14.3.111 · Cited by 3
Expression of the Glucagon Like Peptide-1 Receptor in Human Pancreas and Incretin Therapy
Teitelman, G. (2014) · Endocrinology · doi:10.1210/en.2014-1166 · Cited by 3
Toxicology Assessment of a Dual-Function Peptide 5rolGLP-HV in Mice
Ni, Z., Wang, B., Ma, X., Duan, H., Jiang, P., Li, X., Wei, Q., Ji, X., & Li, M. (2016) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-016-2166-9 · Cited by 3
Pirozzi, F. F. (2015) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.s13-013 · Cited by 4
Sitagliptin related pancreatitis in the elderly: A rare but serious complication
Yen, J. M., Tan, L. F., & Sze, Y. L. (2017) · European Geriatric Medicine · doi:10.1016/j.eurger.2017.07.006 · Cited by 3
Inkretintengelyen ható antidiabetikumok és a pancreas betegségei (pancreatitis, pancreascarcinoma)
Jermendy, G. (2016) · Orvosi Hetilap · doi:10.1556/650.2016.30409 · Cited by 3
Campbell‐Thompson, M., Schatz, D., Kaddis, J. S., & Atkinson, M. A. (2016) · Diabetologia · doi:10.1007/s00125-016-3889-4 · Cited by 3
Self-citationWilliams, J. A. (2014) · doi:10.3998/panc.2014.7 · Cited by 4
Vigara, L. A., Villanego, F., Orellana, C., Eady, M., Sánchez, M. G., Alonso, M., García, M. B., Amaro, J. M., García, T. G., & Mazuecos, A. (2023) · Nefrología · doi:10.1016/j.nefro.2023.06.010 · Cited by 2
Gliptin induced acute pancreatitis: a literature review
Pragadeesh, G. J., Sali, S. A. A., Kumar, S. R., Babu, D., & Dheepthi, D. (2025) · Acta gastro-enterologica belgica · doi:10.51821/88.1.13722 · Cited by 2
Obesity and GEP-NEN: what’s new?
Boschetti, M., Hasballa, I., Patelli, I., Piras, G., & Albertelli, M. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.12.006 · Cited by 3
Chao, D. T., Shah, N. H., Zeh, H. J., Bahary, N., Whitcomb, D. C., & Brand, R. E. (2015) · Pancreas · doi:10.1097/mpa.0000000000000439 · Cited by 2
Incretin Therapy and Beta Cell Function
Goundan, P. N., UNDERWOOD, P. C., & Mantzoros, C. S. (2014) · Metabolism · doi:10.1016/j.metabol.2014.10.006 · Cited by 2
Xie, H., Xu, Q., Zhao, B., & Wu, W. (2025) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2469273 · Cited by 2
The effects of incretins as a double-edged sword on cancer
Mavaddat, H., Fouladi, A., Peyrovinasab, A., Khayatan, I., Targhi, H. J., Fakhri, M., Andarzbakhsh, K., Büsselberg, D., Razavi, S. M., & Rezazadeh, A. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-11062-5 · Cited by 2
Insulin, other hypoglycemic drugs, and glucagon
Page, R. C. (2014) · Side effects of drugs annual · doi:10.1016/b978-0-444-62635-6.00042-5 · Cited by 4
Freichel, M., & Mengel, K. (2014) · Springer eBooks · doi:10.1007/978-3-662-43487-1_11 · Cited by 4
New oral hypoglycaemics fail to show cardiovascular benefits
Cohen, D. R. (2013) · BMJ · doi:10.1136/bmj.f5458 · Cited by 2
Gale, E. A. (2013) · Diabetes Care · doi:10.2337/dc13-1542 · Cited by 2
Clinical Approaches to Preserving β-Cell Function in Diabetes
WAJCHENBERG, B. L., & de Carvalho, R. M. (2014) · Springer eBooks · doi:10.1007/978-94-007-6686-0_17 · Cited by 1
Inglot, T. W. (2025) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-025-00646-9 · Cited by 1
GLP-1 agonists-induced autoimmune pancreatitis
Mahajne, J., Angarola, E., Della‐Torre, E., & Lanzillotta, M. (2025) · BMJ Case Reports · doi:10.1136/bcr-2025-267811 · Cited by 1
GLP-1 agonists-induced autoimmune pancreatitis
Mahajne, J., Angarola, E., Della‐Torre, E., & Lanzillotta, M. (2025) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2025.267811rep · Cited by 1
Wang, Y., Zhang, C., Zhao, H., Wang, C., Guo, L., Wei, P., Jin, M., Li, A., Li, Q., & Pan, H. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1693381 · Cited by 1
Obesity management medications for the surgeon
Harris, M., Mahdi, S., Fairfield, C. J., Brown, L. R., Wadley, M., & Miras, A. D. (2026) · Frontline Gastroenterology · doi:10.1136/flgastro-2025-103307 · Cited by 1
Risk of pancreatic cancer associated with GLP-1 receptor agonist therapy
Krishna, S., Dungan, K. M., Shah, R., Cruz‐Monserrate, Z., DelGiorno, K. E., Tan, M., & Hart, P. A. (2026) · npj gut and liver. · doi:10.1038/s44355-026-00069-9 · Cited by 1
Neue Betazellen dank Peptidhormon?
Simon, M. (2013) · Info Diabetologie · doi:10.1007/s15034-013-0421-5 · Cited by 1
Incretin-Based Therapies: Revisiting Their Mode of Action
Layden, B. T., Wicksteed, B. L., & Mauvais‐Jarvis, F. (2017) · Endocrinology · doi:10.1210/en.2017-00252 · Cited by 1
Freichel, M., & Mengel, K. (2017) · Springer eBooks · doi:10.1007/978-3-662-54630-7_14 · Cited by 1
Freichel, M., & Mengel, K. (2015) · Springer eBooks · doi:10.1007/978-3-662-47186-9_10 · Cited by 1
Linagliptin-Induced Pancreatitis
Sharu, H. E., Hidri, S., Peltz, J., & Alqaisieh, M. H. (2023) · Annals of Internal Medicine Clinical Cases · doi:10.7326/aimcc.2023.0316 · Cited by 1
Freichel, M., & Klinge, A. (2025) · Springer eBooks · doi:10.1007/978-3-662-70594-0_10 · Cited by 2
Antidiabetic agents as potential cytotoxic candidates for cancer therapy
Alnaser, R. I., Alassaf, F. A., & Abed, M. N. (2024) · Forum of Clinical Oncology · doi:10.2478/fco-2023-0041 · Cited by 2
Vaciamiento gástrico y Diabetes mellitus tipo 2
Cadavid, C. A. Q., Regino, W. O., & Vega, R. F. (2015) · Revista de la Facultad de Medicina · doi:10.15446/revfacmed.v63n2.46195 · Cited by 2
George, J. T. (2015) · Practical Diabetes · doi:10.1002/pdi.1976 · Cited by 1
Management of Type 2 diabetes with liraglutide
Bohl, M., Overgaard, A., Pietraszek, A., & Hermansen, K. (2014) · Diabetes Management · doi:10.2217/dmt.13.72 · Cited by 1
Dipeptidyl Peptidase-4 Inhibitor
Lee, D. H. (2014) · Korean Journal of Medicine · doi:10.3904/kjm.2014.87.1.1 · Cited by 1
ABCD position statement on GLP‐1 based therapies and pancreatic damage
Ryder, B., McKnight, J., Blann, A. D., Dhatariya, K., Gregory, R., Robinson, T., Rowles, S. V., Sharp, P. S., Winocour, P. H., & Walton, C. (2013) · Practical Diabetes · doi:10.1002/pdi.1816 · Cited by 2
Glucagon-like peptide-1 based therapies: Effects beyond blood glucose control
Sivaraman, S., Barber, T. M., O'Hare, P. J., & Randeva, H. S. (2013) · The British Journal of Diabetes · doi:10.1177/1474651413504119 · Cited by 1
Incretin for the continuing treatment of secondary failure to metformin in Type 2 diabetes
Gallwitz, B. (2013) · Diabetes Management · doi:10.2217/dmt.13.29 · Cited by 1
Tamaki, C., Takeuchi, M., Iwamoto, N., & Glaesner, W. (2015) · Folia Pharmacologica Japonica · doi:10.1254/fpj.146.215 · Cited by 1
Effects of Linagliptin on Pancreatic α Cells of Type 1 Diabetic Mice
Zhang, Y., Fava, G. E., Wu, M., Htun, W., Klein, T., Fonseca, V. A., & Wu, H. (2017) · Journal of the Endocrine Society · doi:10.1210/js.2017-00253 · Cited by 1
Zhao, D., Zhao, S., Wang, X., Su, M., Liu, W., Ma, Q., Hong, J., Gu, W., Li, J., Liu, R., et al. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00062 · Cited by 1
Molecular Basis of cAMP Signaling in Pancreatic Beta Cells
Holz, G. G., Chepurny, O. G., Leech, C. A., Song, W., & Hussain, M. A. (2014) · Springer eBooks · doi:10.1007/978-94-007-6884-0_25-3 · Cited by 1
Nakagami, T., Ide, R., Iwasaki, N., Ogata, M., Oya, J., Osawa, M., Tanaka, N., Takaike, H., Sato, A., Miura, J., et al. (2013) · Diabetology International · doi:10.1007/s13340-013-0155-6 · Cited by 1
Freichel, M., & Mengel, K. (2019) · Springer eBooks · doi:10.1007/978-3-662-59046-1_15 · Cited by 1
Metabolic syndrome and cancer risk
Majumder, A., & Acharya, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-85732-1.00052-9 · Cited by 1
Investigations editor's reply to Holt and to Barnett and O'Hare
Cohen, D. R. (2013) · BMJ · doi:10.1136/bmj.f4383 · Cited by 1
Müller, T. D. (2014) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2014.914850 · Cited by 2
Nakagami, T., Ide, R., Iwasaki, N., Ogata, M., Oya, J., Osawa, M., Tanaka, N., Takaike, H., Sato, A., Miura, J., et al. (2014) · Diabetology International · doi:10.1007/s13340-014-0159-x · Cited by 1
Potential pancreatic risks with GLP-1-based therapies for T2DM
(2013) · Reactions Weekly · doi:10.1007/s40278-013-2362-0 · Cited by 1
and, S. M., & Currie, G. E. (2022) · Wiley eBooks · doi:10.1002/9781119785033.ch4 · Cited by 3
Was it really pancreatitis from GLP‐1 receptor agonist therapy?
Thong, K. Y., & Ryder, R. E. J. (2013) · Practical Diabetes · doi:10.1002/pdi.1801
Fransson, L. (2014) · Figshare
Glucagon-like peptide-1 in nonalcoholic steatohepatitis
Armstrong, M. J. (2014) · University of Birmingham Institutional Research Archive (University of Birmingham)
Krempf, M. (2014) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(14)70683-2
Glucagon-like Peptide 1–Based Drugs and Pancreatic Safety—Reply
Singh, S. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.8128
Iizuka, K., Niwa, H., Takahashi, Y., & Takeda, J. (2014) · Diabetology International · doi:10.1007/s13340-014-0167-x
Cancers du pancréas et sécurité des incrétines : état des lieux en 2014
Halimi, S. (2014) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(14)70835-1 · Cited by 1
Effect of DPP-4 Inhibitors on the Cardiovascular System, Cancer and Pancreatitis
Cho, E.-H. (2013) · Journal of Korean Diabetes · doi:10.4093/jkd.2013.14.3.138
Welcome Reassurance About GLP-1 Drugs—But They Are Still Young and Not Fully Grown
Riddle, M. C. (2015) · Diabetes Care · doi:10.2337/dc14-2649
Treatments for Type 2 Diabetes; a Focus on DPP4 Inhibitors
TOMKIN, G. H. (2014) · Pharmaceutical Regulatory Affairs Open Access · doi:10.4172/2167-7689.1000114
Simon, M., Roden, M., & Müssig, K. (2013) · Der Diabetologe · doi:10.1007/s11428-013-1058-7
Conversion of pancreatic δ-cells into β-cells
Sakamoto, K. (2015) · Folia Pharmacologica Japonica · doi:10.1254/fpj.145.164
Metadata
- Authors
- Butler, A. E., Campbell-Thompson, M., Gurlo, T., Dawson, D. W., Atkinson, M., & Butler, P. C.
- Affiliations
- University of California, Los Angeles (US)
- Departments of Pathology and Pediatrics, College of Medicine, University of Florida, Gainesville, Florida.
- University of Florida Health (US)
- Corresponding author
- Butler, Alexandra E.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2013-06-14
- Volume
- 62
- Issue
- 7
- Pages
- 2595-2604
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC3712065
- OpenAlex
- W2137982063
- Cited by
- 457
- References
- 35
- Citations by year
- 2026: 18 · 2025: 20 · 2024: 15 · 2023: 12 · 2022: 19 · 2021: 16 · 2020: 20 · 2019: 21 · 2018: 19 · 2017: 25 · 2016: 34 · 2015: 59 · 2014: 99 · 2013: 80
- FWCI
- 90.29
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by-nc-nd)
- Funders
- Larry L. Hillblom Foundation
- National Institute of Diabetes and Digestive and Kidney Diseases (DK-061539, R01DK061539, DK059579, #DK077967, R01DK077967, R01DK059579)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Keywords
- incretin-based therapy, beta-cell mass, pancreatic intraepithelial neoplasia, alpha cell hyperplasia, type 2 diabetes, pancreatic regeneration
- MeSH terms
- Sitagliptin Phosphate, Adenoma, Adolescent, Adult, Aged, Diabetes Mellitus, Type 2, Female, Humans, Hyperplasia, Male, Middle Aged, Organ Size, Pancreas, Pyrazines, Triazoles, Neuroendocrine Tumors, Cell Proliferation, Insulin-Secreting Cells, Incretins, Dipeptidyl-Peptidase IV Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.